Clinical trials: Melanoma of Skin
Melanoma, Breast Cancer
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery.
- Conditions
- Melanoma, Breast Cancer, Uterine Cancer, Ovarian Cancer
- Trial name
- MICROBIOME (NCT03934827)
- Testing
- MRx0518 Capsules
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Metastatic Melanoma Stage IV
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
- Trial name
- NCT02076646
- Testing
- L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC
- Where
- 2 sites in Germany, Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Kidney Cancer, Melanoma (Skin)
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally…
- Trial name
- NCT00492440
- Testing
- recombinant interleukin-7, gene expression analysis, polymerase chain reaction
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytheris SA
Colorectal Cancer Metastatic, Metastatic Melanoma
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial
Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of…
- Conditions
- Colorectal Cancer Metastatic, Metastatic Melanoma, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- PRECISION-F (NCT01932489)
- Testing
- Biopsy of a metastatic lesion.
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Jules Bordet Institute
Melanoma
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor.
- Trial name
- NCT00972933
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Diwakar Davar
Melanoma, Recurrent Melanoma
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
This phase II portion of the trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable…
- Conditions
- Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT01851408
- Testing
- sorafenib tosylate, temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma, Squamous Cell Carcinoma of Skin Differentiated
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
Previous work suggests that topical treatment with 33% hydrogen peroxide can reduce lesion size and, in about half of patients, can cause complete pathologic response.
- Trial name
- NCT04929535
- Testing
- Hydrogen Peroxide 30 % Topical Solution
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Malignant Melanoma Stage III
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
This is an open-label three-arm phase 2 trial (including a Simon stage 2 design) consisting of 90 stage III melanoma patients randomized 1:1:1 to receive either 2 courses 3 mg/kg ipilimumab + 1 mg/kg nivolumab every 3 weeks (Arm…
- Trial name
- OpACIN-neo (NCT02977052)
- Testing
- Ipilimumab, Nivolumab, Surgery
- Where
- 4 sites in Australia, Austria and 2 more
- Volunteers
- 186 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Melanoma
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
The aim of the study BCD-263-1 is to prove the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-263 and Opdivo following intravenous administration to subjects…
- Trial name
- NCT06112808
- Testing
- BCD-263, Opdivo
- Where
- 30 sites in Belarus, Russia
- Volunteers
- 300 people
- Sponsor
- Biocad
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Melanoma, Sentinel Node
Infrared Lymphangiography as a Method of Sentinel Node Identification
The initial treatment for most people with melanoma involves wide excision of the skin and sentinel node biopsy. As with other cancers, the status of the sentinel node provides important prognostic information to the patient and…
- Trial name
- SPY-SN (NCT02057393)
- Testing
- Indocyanine green, Technetium99, Methylene blue
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Milton S. Hershey Medical Center
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Melanoma (Skin)
Gene Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00005943
- Testing
- aldesleukin, staphylococcal enterotoxin B
- Where
- United States
- Sponsor
- University of Colorado, Denver
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00033228
- Testing
- MKC1106-MT
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating…
- Trial name
- NCT00089219
- Testing
- IFA, 6MHP, GM-CSF
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Virginia
Melanoma
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.
- Trial name
- NCT05051865
- Testing
- camrelizumab, SHR1020
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Basal Cell Carcinoma, Melanoma
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
The purpose of this study is to image skin and skin lesions with a new imaging technology called "multiwavelength and coherence confocal reflectance microscopy".
- Conditions
- Basal Cell Carcinoma, Melanoma, Non-Malignant Skin Disorders, Squamous Cell Carcinoma
- Trial name
- NCT00574392
- Testing
- Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.